Lineage Cell Therapeutics Inc (LCTX)

2.87
+0.06(+2.14%)
After Hours
2.88
+0.01(+0.3484%)
- Real-time Data
  • Volume:
    1,081,997
  • Bid/Ask:
    2.87/2.95
  • Day's Range:
    2.805 - 2.92

LCTX Overview

Prev. Close
2.81
Day's Range
2.805-2.92
Revenue
1.7M
Open
2.84
52 wk Range
0.73-3.1316
EPS
-0.09
Volume
1,081,997
Market Cap
465.35M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,183,061
P/E Ratio
-
Beta
1.88
1-Year Change
187.37%
Shares Outstanding
162,141,197
Next Earnings Date
Aug 12, 2021
What is your sentiment on Lineage Cell Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Lineage Cell Therapeutics Inc News

Lineage Cell Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsBuySellStrong BuyStrong BuyStrong Buy
SummaryStrong BuyNeutralStrong BuyStrong BuyStrong Buy

Lineage Cell Therapeutics Inc Company Profile

Lineage Cell Therapeutics Inc Company Profile

Employees
49

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. It has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Read More
  • We waited 100 days and went back to 3 usd
    0
    • and? Are you holding or selling? What is your pt?
      0
  • why nobody comments this good result?
    0
    • i wait for 5 usd. until 2022
      0
      • dont wait for 3 usd
        1
        • we need another spike to 3$
          0
          • Hello any news from your side?
            0
        • after 7 dsys of declines it is clear ee have been captured by a digital organization of bad people
          0
          • Why is this?
            0
        • I can’t find something that will help me understand what was the reason she started to fly
          0
          • because it is a good stock to hold long and strong
            0
        • why is it down
          2
          • there does not seem to be a justifiable reason other than the difficulty of getting on without taking air on the way.let's hope for the best
            0
          • difficulty of getting on without taking air on the way.
            0
        • We are really close to $3 but then¿ I seethe avg target price is $5.25 and the highest $7...any thoughts?
          0
          • Hello everybody, any news after the spike to 2.01?
            0
            • שלמה אביבי Hello, what is your tp¿?
              0
            • שלמה אביבי  hello, what is your tp?
              0
            • שלמה אביבי hello, any good news coming? I dont understand the big pull back from above the $3
              0
          • Should hae another pump on 2nd Green day here, hey?
            0
            • Strong buy !
              0
              • going long with this
                1
                • Hey
                  1
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.